Cargando…
Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
During their development and progression tumors acquire numerous mutations that, when translated into proteins give rise to neoantigens that can be recognized by T cells. Initially, neoantigens were not recognized as preferred targets for cancer immunotherapy due to their enormous diversity and the...
Autores principales: | Wirth, Thomas C., Kühnel, Florian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742119/ https://www.ncbi.nlm.nih.gov/pubmed/29312332 http://dx.doi.org/10.3389/fimmu.2017.01848 |
Ejemplares similares
-
mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
por: Deng, Zhuoya, et al.
Publicado: (2022) -
Mutation-Derived Neoantigens for Cancer Immunotherapy
por: Castle, John C., et al.
Publicado: (2019) -
Neoantigen: A New Breakthrough in Tumor Immunotherapy
por: Zhang, Zheying, et al.
Publicado: (2021) -
Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?
por: Roerden, Malte, et al.
Publicado: (2019) -
The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy
por: Karpanen, Terhi, et al.
Publicado: (2017)